Licensed Producers Canada

Welcome. First, a quick age check.

LPC publishes independent cannabis information. Some sections are intended for adults of legal cannabis age in their province or territory.

18+ Alberta 21+ Quebec 19+ elsewhere in Canada

Are you of legal cannabis age where you live?

Anyone can read youth health guidance and confidential support or public cannabis education without confirming their age.

This is a self-declaration, not proof of identity. My LPC membership has a separate, server-checked provincial age requirement. Your public choice stays in this browser.

Skip to content
Today's dateToday
WestVancouver
EastToronto
AtlanticHalifax
Outdoor seasonPost-harvestSeasonResources

LPC News archive · Historical article

Short seller Andrew Left has his doubts about Canadian pot stocks, says he’s betting against Canopy

Citron Research’s Andrew left reiterated his bet against the Canadian cannabis industry Wendesday, telling CNBC that he’s short Canopy Growth and Cronos Group in addition to his already disclosed wager against Tilray .

Fielding a question from " Halftime Report " host Scott Wapner, Left said his doubts on the space aren’t confined to just one company.

"I’m also short Cronos, I’m short Canopy, I’m short Tilray. So I’m short a basket of the names," he said. "Once the U.S. licensed producers come on — the faster it becomes legal in the U.S., the quicker the Canada names go lower."

"They won’t get the exposure in the U.S., they’re not players internationally," Left added. "I don’t care how many press releases they put out, they’re not going to be shipping cannabis from Canada to Australia. Not happening."

Shares of the three Canada-based marijuana producers sank Wednesday between Left’s comments and Canopy Growth’s earnings results. Tilray shed 11 percent and Canopy fell 15 percent in the U.S., while Cronos dropped 5.4 percent in Toronto.

Left’s midday remarks came hours after Canopy Growth’s second-quarter revenues results missed even the most conservative Wall Street estimate.

The company’s total revenue of 23.3 million Canadian dollars fell well short of the average analyst expectation of CA$60 million despite growing 33 percent from the prior year’s second quarter. The results represent Canopy’s first sequential top-line decline.To be sure, only a few analysts cover Canopy, a fact that makes any consensus projection less precise."With business opportunities expanding globally, we continue to make […]

Click here to view full story at www.cnbc.com

External sites may have changed or removed their content since this article was published.

Continue exploring LPC

Read the latest evidence-based reporting or discover curated Health Canada-matched Licensed Producers.